|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Agent 8/03/18 Sienna Biopharmaceuticals, Inc. S-3 7:1.4M Donnelley … Solutions/FA |
Document/Exhibit Description Pages Size
1: S-3 Registration Statement for Securities Offered HTML 271K
Pursuant to a Transaction
2: EX-1.2 Underwriting Agreement HTML 142K
3: EX-4.4 Instrument Defining the Rights of Security Holders HTML 192K
4: EX-5.1 Opinion re: Legality HTML 25K
6: EX-23.1 Consent of Experts or Counsel HTML 5K
7: EX-25.1 Statement re: Eligibility of Trustee -- Form T-1|2 HTML 103K
5: EX-12.1 Statement re: Computation of Ratios HTML 14K
| EX-12.1 |
Exhibit 12.1
STATEMENT REGARDING THE COMPUTATION OF RATIOS
Our earnings are inadequate to cover combined fixed charges and preference dividends. The following table sets forth the dollar amount of the deficiency (in thousands) to cover fixed charges for the periods indicated.
| Three Months Ended March 31, |
Year Ended December 31, | |||||||||||||||
| 2018 | 2017 | 2016 | 2015 | |||||||||||||
| EARNINGS: |
||||||||||||||||
| Net loss before taxes |
$ | (17,103 | ) | $ | (50,835 | ) | $ | (21,162 | ) | $ | (11,294 | ) | ||||
| Plus fixed charges |
16 | 845 | 32 | 555 | ||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Earnings as defined |
$ | (17,087 | ) | $ | (49,990 | ) | $ | (21,130 | ) | $ | (10,739 | ) | ||||
| FIXED CHARGES: |
||||||||||||||||
| Interest expense & amortization of debt issuance costs |
$ | — | $ | 763 | $ | — | $ | 547 | ||||||||
| Estimated interest component of rental expense(1) |
16 | 82 | 32 | 8 | ||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Total fixed charges |
$ | 16 | $ | 845 | $ | 32 | $ | 555 | ||||||||
| RATIO OF EARNINGS TO FIXED CHARGES |
N/A | N/A | N/A | N/A | ||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
Earnings were insufficient to cover fixed charges by $17.1 million for the three months ended March 31, 2018, $50.8 million in 2017, $21.2 million in 2016, and $11.3 million in 2015.
| (1) | Represents the estimated portion of operating lease rental expense that is considered by us to be representative of interest. |
For the periods indicated above, we had no outstanding shares of preferred stock with required dividend payments. Therefore, the ratios of earnings to combined fixed charges and preferred stock dividends are identical to the ratios presented in the tables above.
| This ‘S-3’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| 12/31/18 | ||||
| Filed on: | 8/3/18 | |||
| 3/31/18 | 10-Q | |||
| List all Filings | ||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 8/09/18 SEC UPLOAD¶ 9/13/18 1:44K Sienna Biopharmaceuticals, Inc. |